ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 这项研究是为了比较抗艾滋病毒药物组合的有效性，安全性和耐受性。本研究将使用以下药物和药物组合： " 依法韦仑（EFV）联合恩曲他滨（FTC）和替诺福韦（TDF） " EFV联合阿巴卡韦（ABC）和拉米夫定（3 TC） " 阿扎那韦（ATV）联合利托那韦（RTV）和FTC/TDF " ATV与RTV和ABC/3 TC 所有这些药物都被FDA批准用于治疗HIV。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to compare the effectiveness, safety, and tolerability of anti-HIV drug combinations. The following drugs and drug combinations will be used in this study: " Efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) " EFV with abacavir (ABC) and lamivudine (3TC) " Atazanavir (ATV) with ritonavir (RTV) and FTC/TDF " ATV with RTV and ABC/3TC All of the drugs are approved by the FDA for treating HIV.